Cboe UK • CHF Sandoz Group AG (SDZZ.XC) Follow Compare 42.92 +0.35 +(0.82%) At close: 4:19:58 PM GMT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for SDZZ.XC 1D 5D 5.12% 1M 15.87% 3M 12.92% 6M 23.97% YTD 16.09% 1Y 47.24% 5Y 51.98% All 51.98% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: SDZZ.XC View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference RBC buyers of Intra-Cellular after ‘more favorable-than-expected’ settlement Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Strong Buy: Here's What You Should Know Here's Why Sandoz Group AG Sponsored ADR (SDZNY) Is a Great 'Buy the Bottom' Stock Now Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio Sandoz reports third-quarter and nine-month 2024 sales Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio Introducing Jubbonti® and Wyost®, the first denosumab biosimilars on the Canadian market Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position Sandoz reports second-quarter sales and half-year 2024 results Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases